Literature DB >> 9379387

Laser in situ keratomileusis after automated lamellar keratoplasty and penetrating keratoplasty.

A Parisi, D J Salchow, M E Zirm, C Stieldorf.   

Abstract

We present three patients who had laser in situ keratomileusis (LASIK) after corneal surgery as follow: 15 months after automated lamellar keratoplasty (ALK) for hyperopia, 6 months after ALK for hyperopia, and 2 years after penetrating keratoplasty (PKP). Although the first case was uneventful, intraoperative complications arose in the second case because the connection of the ALK-related flap to its stromal bed was insufficient. In the third case, the refractive error caused by PKP was corrected as shown by corneal topography and visual acuity measurement. In conclusion, LASIK after PKP can be considered a precise and safe procedure if 2 to 3 years pass between the procedures. An interval of 6 months between ALK and LASIK was too short, whereas 15 months after ALK for hyperopia, LASIK was performed without problems and delivered a good result.

Entities:  

Mesh:

Year:  1997        PMID: 9379387     DOI: 10.1016/s0886-3350(97)80090-9

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  4 in total

1.  LASIK for post penetrating keratoplasty astigmatism and myopia.

Authors:  S K Webber; M A Lawless; G L Sutton; C M Rogers
Journal:  Br J Ophthalmol       Date:  1999-09       Impact factor: 4.638

2.  Long-term analysis of LASIK for the correction of refractive errors after penetrating keratoplasty.

Authors:  David R Hardten; Anuwat Chittcharus; Richard L Lindstrom
Journal:  Trans Am Ophthalmol Soc       Date:  2002

3.  Visual outcomes of Femto-LASIK for correction of residual refractive error after corneal graft.

Authors:  Mohammad Ghoreishi; Afsaneh Naderi Beni; Zahra Naderi Beni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-09-26       Impact factor: 3.117

4.  Current approaches for management of postpenetrating keratoplasty astigmatism.

Authors:  Sepehr Feizi; Mohammad Zare
Journal:  J Ophthalmol       Date:  2011-07-27       Impact factor: 1.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.